自发性脑出血患者的颅内压监测:SYNAPSE-ICU研究启示
SYNAPSE-ICU研究前瞻性观察587例自发性脑出血患者,281例(47.9%)接受颅内压监测。监测组6个月死亡率显著降低(HR 0.49,95%CI 0.35-0.71),但6个月神经功能结局无显著改善(OR 0.83,95%CI 0.41-1.68)。
要点
- 颅内压监测主要用于中等严重程度的脑出血患者。
- 监测组6个月死亡率显著降低,但功能结局无显著改善。
- 需进一步随机对照试验为颅内压监测指南提供高级别证据。
核心结论
- 颅内压监测与院内及6个月死亡率降低相关,但未改善6个月功能结局。
- 需要进一步研究和随机对照试验以生成更高级别医学证据支持颅内压使用和治疗的指南。
研究设计与样本
- SYNAPSE-ICU研究是一项关于颅内压监测使用的国际前瞻性观察性研究。
- 本研究纳入587例入住重症监护室的自发性脑出血患者,其中281例(47.9%)接受颅内压监测。
- 采用倾向评分逆概率加权方法评估颅内压监测与6个月死亡率和结局的关联。
主要发现
- 监测组较非监测组更年轻(61岁 vs 67岁;p < 0.001)。
- 监测组较非监测组瞳孔有反应者更多(67.2% vs 55.2%;p = 0.008)。
- 监测组较非监测组入院时格拉斯哥昏迷评分≤8分者更少(82.3% vs 88.8%;p = 0.038)。
- 46.6%的监测患者在第一周至少有一次颅内压≥20 mm Hg发作。
- 加权Cox回归模型中,颅内压监测与6个月死亡率显著降低相关(风险比 0.49 [95% CI 0.35-0.71;p = 0.001]),但与神经功能结局无关(比值比 0.83 [95% CI 0.41-1.68];p = 0.6077)。
关键数值与推荐
- 在241例接受颅内压监测的患者中,70.5%(170例)的脑出血评分等于3或4。
- 脑室导管(53.6%)是最常用的监测装置,与其他监测装置相比与更少的颅内高压发作相关(43.7% vs 64.9%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究和随机对照试验以生成更高级别医学证据支持颅内压使用和治疗的指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uncertainties exist regarding the indications, management, and effect of intracranial pressure (ICP) monitoring and treatment on outcome in patients with spontaneous intracranial hemorrhage (ICH). METHODS: We performed an analysis of patients with spontaneous ICH enrolled in the SYNAPSE-ICU study, an international prospective observational study on the use of ICP monitoring. This study aimed to describe, in a large cohort of patients with spontaneous ICH admitted to the intensive care unit (ICU), the clinical practice of ICP monitoring, the occurrence of intracranial hypertension, and its therapeutic management. We assessed in-hospital mortality and the association between ICP monitoring and 6-month mortality and outcome by a propensity score approach with inverse probability weighting. RESULTS: A total of 587 patients with ICH were included in this study; 281 (47.9%) received ICP monitoring. ICP-monitored patients, compared with nonmonitored patients, were younger (61 vs 67 years; p < 0.001), presented more frequently with both reactive pupils (67.2% vs 55.2%; p = 0.008), with better neurologic status at admission (Glasgow Coma Scale ≤8, 82.3% vs 88.8%; p = 0.038), and received higher therapy intensity level during the ICU stay. In 70.5% (170 out of 241) of ICP-monitored patients, the ICH score was equal to 3 or 4. Nearly half of monitored patients (46.6%) had at least one episode of ICP ≥20 mm Hg during the first week. An intraventricular catheter (53.6%) was the most frequently used device and was associated with fewer episodes of intracranial hypertension compared with the other monitoring devices (43.7% vs 64.9%, respectively). At weighted Cox regression model, ICP monitoring was associated with a significant reduction of 6-month mortality (hazard ratio 0.49 [95% CI 0.35-0.71; p = 0.001), but not with neurologic outcome (odds ratio 0.83 [95% CI 0.41-1.68]; p = 0.6077). CONCLUSIONS: ICP monitoring in ICH was utilized mainly in moderately severe cases. ICP monitoring was associated with a reduction of in-hospital and 6-month mortality but did not improve 6-month functional outcomes. Further research and randomized controlled trials to generate higher-level medical evidence to support guidelines regarding ICP use and treatment in patients with ICH are needed. TRIAL REGISTRATION INFORMATION: SYNAPSE-ICU: ClinicalTrials.gov NCT03257904.
引用
- Dallagiacoma S, Robba C, Graziano F, et al. Intracranial Pressure Monitoring in Patients With Spontaneous Intracerebral Hemorrhage: Insights From the SYNAPSE-ICU Study. Neurology. 2022. PMID: 35508390. doi:10.1212/WNL.0000000000200568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。